PolarityTE Inc.

PolarityTE — Investor Presentation (September 2022)

36 slides from PolarityTE's investor presentation, Sep 12, 2022

  1. Slide 1: Investor Presentation September 2022

    kj * Investor le Presentation September 2022

  2. Slide 2: Forward looking statement

    Se SeF Ser - This presentation contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties and investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Forward-looking statements are no

  3. Slide 3: SkinTE: Highly differentiated, real-world tested asset

    SkinTE® Highly differentiated, real-world tested asset with significant market opportunity Phase 3 IND approved Jan 2022 v First pivotal trial — COVER DFUs — commenced enrollment in early Q2 2022 v RMAT Designation Granted May 2022 for DFU and VLU Body of scientific and Real world clinical evidence

  4. Slide 4: Chronic Wounds: A large and growing health and economic problem

    6.5M Affected Patients in the US per year ~2.4M Annual Incidence Rate of DFUs ~2.5M Annual Incidence Rate of Pressure Injury Chronic Wounds A large and growing health and economic problem Types of Chronic Wounds Diabetic Foot Ulcers Venous Leg Ulcers Pressure Injuries More than Chronic wounds are $2

  5. Slide 5: SkinTE for Diabetic Foot Ulcers represents a significant commercial opportunity

    34M Diabetics in the United States? 2.2M DFU Annual Incidence Rate* SkinTE® for Diabetic Foot Ulcers represents a significant commercial opportunity Current products and Trials are Largely Focused on Wagner 1 DFUs and Primarily in the Outpatient Setting of Care! 75% of actual wound ~46% of DFUs 160K

  6. Slide 6: Why Wagner 2 and 3?

    Why Wagner 2 and 3? Because the most severe Diabetic Foot Ulcers are the true need. Need for Treatments with Clinical Versatility Across Settings of Care CDC reports 130K yearly amputations and 80% were attributed to the 160K inpatient population with diabetic foot ulcer diagnosis.34 22.7% of Wagner

  7. Slide 7: SkinTE is designed to address limitations of current treatments

    —_—-— a Sob == _— ~ Current treatments are not sufficient for true healing SkinTE® is designed to address limitations of current treatments PRODUCT LIMITATIONS SKINTE® ATTRIBUTES Mimic dermal component of skin with no epidermis Autologous and engrafts contributing Skin Substitutes Rely on wound bed

  8. Slide 8: SkinTE: A new approach to hard-to-heal chronic and acute wounds

    SkinTE® A new approach to hard-to-heal chronic and acute wounds of deep wounds and —_ Closure from the Application in a exposed structures * —_— — F inside out single visit in any | setting of care | Treatment Results in Fully Functional Skin SkinTE® is Available for Investigational Use Only Que

  9. Slide 9: Available for Investigational Use Only

    Available for Investigational Use Only

  10. Slide 10: Regenerative potential of skin

    Regenerative potential of skin FOLLICULAR BULGE CELLS ADIPOSE DERIVED CELLS

  11. Slide 11: Limits of endogenous healing

    Limits of endogenous healing We ate Ay’

  12. Slide 12: Goals of therapy

    Goals of therapy >) Epithelium that prevents bacterial penetration and retains moisture >) Dermis that is durable yet flexible >) Dermal appendages that facilitate moisture and thermal regulation and sensation © 2022 PolarityTE, Inc.All Rights Reserved. For Investors Only. Not For General Distributi

  13. Slide 13: Development of SkinTE: Address Limitations of Existing Treatments

    Development of SkinTE®—Address Limitations of Existing Treatments Epidermis EPIDERMAL ~< CELLS ot FOLLICULAR BULGE CELLS Single-Cell Suspension ADIPOSE DERIVED

  14. Slide 14: SkinTE Autologous Heterogeneous Skin Construct (AHSC)

    SkinTE® Autologous Heterogeneous Skin Construct (AHSC) Multicellular segments with endogenous cellular skin populations including keratinocytes, fibroblasts, endothelial cells, follicular cells, and extracellular matrix Not cultured ex vivo - engrafts and expands in the wound bed Multicellular segme

  15. Slide 15: Engraftment of healthy autologous SkinTE multicellular segments

    Engraftment of healthy autologous SkinTE multicellular segments Mechanism of action Developed through extensive in vitro and in vivo research and testing Proliferation and SkinTE expresses growth factors, migration of the SkinTE cytokines, and extracellular matrix cellular populations supporting the

  16. Slide 16: SkinTE process & QA release testing

    SkinTE® process & QA release testing Purity Identity Potency SkinTE is manufactured SkinTE is tested to ensure it SkinTE is tested to aseptically and is tested for has the necessary epidermal and ensure cellular viability bacterial contamination dermal cellular components and cellular activation Ski

  17. Slide 17: Closure — not contracture — from the inside out

    Closure — not contracture — from the inside out >) SkinTE Progression of Closure and Remodeling of a 200 cm2 Wound Over 13 Months? Punch Biopsy of a region treated with SkinTE — six months following deployment with Highlighting Rete Pegs’ HYPODERMIS correlative histology’ © 2022 PolarityTE, Inc.All

  18. Slide 18: SkinTE Published clinical data

    SkinTE® Published clinical data = BRS 5 ORIGINAL ARTICLE: | Reconstructive. Sie Openabel Venous Leg Ulcer Pilot Study Using a Regeneration of Functional, Full-Thickness Novel Autolologous Homologous Skin Construct erty a wiey A multicentre, randomised controlled clinical trial ‘evaluating the effect

  19. Slide 19: SkinTE DFU Randomized Controlled Trial (RCT)

    SkinTE® DFU Randomized Controlled Trial (RCT) Statistically Significant Results 70% Closure with AHSC Primary Endpoint Closure at 12 Weeks AHSC 35/50 (70%) Closed soc 17/50 (34%) Closed p=0.00032 GREATER PAR with AHSC Secondary Endpoint Increased Percent Area Reduction (PAR) at 4, 6, 8, 10 and 12 We

  20. Slide 20: SkinTE Venous Leg Ulcer RCT

    SkinTE® Venous Leg Ulcer RCT Statistically Significant Results ™M% Closure with AHSC Primary Endpoint Closure at 12 Weeks AHSC 10/14 (71%) Closed soc 5/15 (33%) Closed p=0.046 GREATER PAR with AHSC Secondary Endpoint Increased Percent Area Reduction (PAR) at 4, 6, 8, 10 and 12 Weeks p=0.000035 93% S

  21. Slide 21: SkinTE for Complex Diabetic Foot Ulcers

    SkinTE® for Complex Diabetic Foot Ulcers © Success in closing DFUs in randomized controlled trial and real-world evidence2!2 © 2022 Polarity, Inc.All Rights Reserved. For Investors Only. Not For General Distribution, DFU Outcomes from Pilot Trial? Initial wound ~9 weeks after single application of S

  22. Slide 22: DFU Phase III Pivotal Trial Timeline

    SkinTE® DFU Phlll Pivotal Trial Timeline RMAT Designation Received April 2022 Diabetic Foot Ulcers Ji 2022 2 2022 3/Q4 2023 2/Q3 2024 First Phill - Wagner 2 came 2 ea ore Aiming to commence study in Diabetic Foot Ulcers early 2023. Timing, size and January 2022 a a Second Phlll — Wagner 3 duration i

  23. Slide 23: SkinTE Pipeline

    SkinTE® Pipeline Product SkinTE SkinTE POC SkinTE Cryo Indication / Application Other Chronic Wounds (ex. Pressure Injuries, Venous Leg Ulcer) Acute/Traumatic Wounds Burns Point-of-care device for on-site SkinTE processing and deployment Cryopreservation of SkinTE for multiple deployments on a singl

  24. Slide 24: SkinTE for Pressure Injury

    SkinTE® for Pressure Injury g J ty Initial wound ~11 weeks after ~23 weeks after >) Real world evidence supports proof single application single application i ini of SkinTE of SkinTE of concept in pressure injury 22 23 Sacral Pressure Injury’ >] Only 30% of stage IV ulcers heal within 6 months with

  25. Slide 25: SkinTE shows success for additional treatments

    SkinTE® shows success for additional treatments ~84K TRAUMA CASES per year 26 SkinTE has been successfully deployed in clinical use for acute traumatic wounds \ Initial wound ~11 weeks after ~16 weeks after SkinTE SkinTE ~42K BURN CASES per year applicable for SkinTE Initial wound SKINTE FOR BURNS S

  26. Slide 26: Management team with deep operational, clinical, and R&D experience

    Management team with deep operational, clinical, and research and development experience a ae Sy ww 7 Z 7 s Richard Hague Jacob Patterson Nikolai Sopko, Ryan Mathis, Kolby Day, JD Chief Executive Chief Financial Officer MD, PhD MD Senior Vice President GificeriatPrasident Chief Scientific Officer Ch

  27. Slide 27: Board of directors

    Peter Cohen, MBA Chairman of the Board & Chairman of Compensation Committee + Former Board Member of the NYSE + Former Chairman of Shearson Lehman Hutton, Inc. + Former Chairman and CEO of Cowen Inc. + Vice Chairman and Lead Director of the Board of Directors of Scientific Games Corporation + Federa

  28. Slide 28: Poised for success with a novel and proven technology

    Poised for success with a novel and proven technology BUILDING THE FOUNDATION IND Approved & RMAT Designation Granted SkinTE IND Accepted for Chronic Cutaneous Ulcers; First Phase 3 Clinical Trial in Wagner 2 DFUs Commenced in Q2 2022; RMAT Designation Granted in Q2 2022 ~1,200 Clinical Cases Focuse

  29. Slide 29: Slide 29

  30. Slide 30: PolarityTE

    io) PolarityTE

  31. Slide 31: PolarityTE History

    9 Founded in 2016 by MD/PhD from Johns Hopkins “oe? Autologous cell & tissue technology platform for skin regeneration ns SkinTE® was previously marketed as 361 HCT/P— 1,200 patients treated r Pivoted to 351/BLA pathway—off market as 361 HCT/P in May 2021 after end of enforcement discretion Polarity

  32. Slide 32: Peer reviewed publications

    Peer reviewed publications ‘A multicentre, randomised controlled clinical trial evaluating the effects of a novel 8. "What to put on (and what to take off) a wound: treating a chronic neuropathic ulcer autologous, heterogeneous skin construct in the treatment of Wagner one diabetic with an autologou

  33. Slide 33: Activation of wound healing pathways

    Activation of wound healing pathways Gene Expression Gene Expression Mass Spectrometry Array Stem Cell Array Extracellular Protein Profiling Pathways Matrix Pathways

  34. Slide 34: Extensive in vivo research and testing

    Extensive in vivo research and testing Xenograft Mouse Model Advanced Dressing SkinTE Swine Models swas35 AS 36 cm2 full-excisional wounds Arms: Dressing vs SkinTE + Dressing SWa535 AZ SW8535 AS SkinTE 1:36 expansion ratio rosie

  35. Slide 35: References

    References 1. Sen, Chandan K. “Human Wounds and Its Burden: An Updated Compendium of Estimates.” Advances in wound care vol. 8,2 (2019): 39-48. doi:10.1089/wound.2019.0946 2. Armstrong, David G et al. “Complete wound closure following a single topical application of a novel autologous homologous ski

  36. Slide 36: References (continued)

    References (continued) 18 VanGilder C, Macfarlane GD, Meyer S. Results of nine international pressure ulcer prevalence surveys: 1989 to 2005. Ostomy Wound Manage. 2008;54(2):40-54. 19. Bates-Jensen BM, Guihan M, Garber SL, Chin AS, Burns SP. Characteristics of recurrent pressure ulcers in veterans w

PolarityTE — Investor Presentation (September 2022) on 6ix